Tharimmune Shares Climb on Positive Feedback From EMA on Potential Pruritus Therapy

MT Newswires Live10-30

Tharimmune (THAR) shares climbed by more than 130% in recent Wednesday trading after the company said it received "positive feedback" from the European Medicines Agency about TH104, its candidate to treat moderate-to-severe pruritus in primary biliary cholangitis, or PBC.

The feedback came in a Scientific Advice meeting, the company said, where the agency provided guidance on a planned phase 2 trial to advance TH104.

The agency noted that there was no need to conduct additional animal studies and considered human exposure adequate to move forward, the company added.

Tharimmune said it plans to start a phase 2 multiple-ascending dose trial in the coming months to evaluate the safety and tolerability of TH104, and expects topline data in 2025.

Price: 4.46, Change: +2.44, Percent Change: +120.79

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479733406?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-30 23:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479733406","market":"sg","top_or_hot":-1,"title":"Tharimmune Shares Climb on Positive Feedback From EMA on Potential Pruritus Therapy","media":"MT Newswires Live","content":"<html><body><p> Tharimmune (THAR) shares climbed by more than 130% in recent Wednesday trading after the company said it received \"positive feedback\" from the European Medicines Agency about TH104, its candidate to treat moderate-to-severe pruritus in primary biliary cholangitis, or PBC.</p><p>The feedback came in a Scientific Advice meeting, the company said, where the agency provided guidance on a planned phase 2 trial to advance TH104.</p><p>The agency noted that there was no need to conduct additional animal studies and considered human exposure adequate to move forward, the company added.</p><p>Tharimmune said it plans to start a phase 2 multiple-ascending dose trial in the coming months to evaluate the safety and tolerability of TH104, and expects topline data in 2025.</p><p>Price: 4.46, Change: +2.44, Percent Change: +120.79</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tharimmune Shares Climb on Positive Feedback From EMA on Potential Pruritus Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTharimmune Shares Climb on Positive Feedback From EMA on Potential Pruritus Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-30 23:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tharimmune (THAR) shares climbed by more than 130% in recent Wednesday trading after the company said it received \"positive feedback\" from the European Medicines Agency about TH104, its candidate to ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"THAR","symbol_name":"Tharimmune Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2479733406","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479733406","pubTimestamp":1730300791,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tharimmune  shares climbed by more than 130% in recent Wednesday trading after the company said it received \"positive feedback\" from the European Medicines Agency about TH104, its candidate to treat moderate-to-severe pruritus in primary biliary cholangitis, or PBC.The feedback came in a Scientific Advice meeting, the company said, where the agency provided guidance on a planned phase 2 trial to advance TH104.The agency noted that there was no need to conduct additional animal studies and considered human exposure adequate to move forward, the company added.Tharimmune said it plans to start a phase 2 multiple-ascending dose trial in the coming months to evaluate the safety and tolerability of TH104, and expects topline data in 2025.Price: 4.46, Change: +2.44, Percent Change: +120.79","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"THAR":"Tharimmune Inc.","BK4139":"生物科技"},"translate_title":"由于EMA对潜在瘙痒疗法的积极反馈，Tharimmune股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"THAR":0.9},"content_text":"Tharimmune (THAR) shares climbed by more than 130% in recent Wednesday trading after the company said it received \"positive feedback\" from the European Medicines Agency about TH104, its candidate to treat moderate-to-severe pruritus in primary biliary cholangitis, or PBC.The feedback came in a Scientific Advice meeting, the company said, where the agency provided guidance on a planned phase 2 trial to advance TH104.The agency noted that there was no need to conduct additional animal studies and considered human exposure adequate to move forward, the company added.Tharimmune said it plans to start a phase 2 multiple-ascending dose trial in the coming months to evaluate the safety and tolerability of TH104, and expects topline data in 2025.Price: 4.46, Change: +2.44, Percent Change: +120.79","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479733406"}